MORE►
Colossal Biosciences
The Form Bio leadership team includes (from left) Andrew Busey, co-CEO; Brandi Cantarel, director of bioinformatics; Kent Wakeford, co-CEO; Claire Aldridge, chief strategy officer; and Ben Lamm, co-founder, who's also the founder and CEO of Colossal Biosciences. [Photo: John Davidson/Form Bio]
Google Cloud Launches AI-Powered Multiomics Suite, Taps Dallas-Based Colossal and Form Bio To Help Accelerate Life Science Research
by David Seeley | May 19, 2023
Google Cloud has unveiled its AI-powered Multiomics Suite, which aims to accelerate the discovery and interpretation of genomic data, helping companies design precision treatments. As part of the rollout, Google Cloud noted that Dallas-based Colossal Biosciences has adopted the Multiomics Suite, and that Colossal spinout Form Bio has been selected to help other organizations adopt it. See what the new suite can do—and how it could help life get scienced.
by David Seeley |
Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
MORE►
by Kevin Cummings |
Oct 24, 2022
The Biotech+ Hub at Pegasus Park in Dallas has been attracting more and more life science startups and university teams. Now a whole herd of Mustangs are about to stampede there. The SMU Institute for Computational Biosciences at Pegasus Park will have space at the 23-acre development. SMU researchers from a variety of disciplines will be focusing on bio-scientific discoveries, leveraging advanced computational algorithms and technologies.
"We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa. "We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa.
"We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa. "We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa.
MORE►
by Kevin Cummings |
Oct 17, 2022
In this week’s North Texas deal flow, you’ll also find news about Mavenir’s $155M raise, Pinnacle Realty Advisors raising $5M for ‘brokerage-as-a-service’ platform, Exela Technologies taking its European business unit public, American Airlines’ hydrogen fuel distribution investment, and more.
MORE►
Colossal co-founder and CEO Ben Lamm. [Image: Colossal]
The Last Word: Colossal’s Ben Lamm on Seeing His Startup Fuel a ‘Jeopardy’ Answer
by David Seeley | Oct 3, 2022
In August, Colossal Biosciences announced it is working to "de-extinct" the Tasmanian tiger with the help of an Australian university and “marsupial biobanking.” It didn't take long for the TV show "Jeopardy" to notice—and work it into an answer.
MORE►
by David Seeley |
Aug 16, 2022
Colossal is already working to "de-extinct" the woolly mammoth via a mammoth-elephant hybrid project. Now the Tasmanian tiger—which went extinct nearly 100 years ago due to human hunting—is the second species Colossal is seeking to bring back.
"We’re thrilled to be collaborating with Andrew Pask and the University of Melbourne to restore this amazing animal to Earth," said Ben Lamm, Colossal's co-founder and CEO.
MORE►
by Quincy Preston and David Seeley |
Mar 22, 2022
Dallas' status as a growing biotech center got a lift with the official opening of BioLabs, a new coworking space at the Biotech+ Hub at Pegasus Park. The 37,000-square-foot facility offers shared wet labs and office space for up to 35 life science startups.
BioLabs' goal: to serve as the epicenter for life science innovation in North Texas, and to empower biotech trailblazers pursing their next breakthrough.
BioLabs' goal: to serve as the epicenter for life science innovation in North Texas, and to empower biotech trailblazers pursing their next breakthrough.
MORE►
by Quincy Preston and David Seeley |
Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►
